Brickell Biotech Inc (BBI) |
|
0.8369 0.009 (1.1%)
|
08-14 16:00 |
|
Open: |
0.83 |
Pre. Close: |
0.8278 |
|
High:
|
0.8537 |
Low:
|
0.8276 |
|
Volume:
|
281,671 |
Market Cap:
|
23M |
|
|
|
|
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead products candidate is sofpironium bromide that is in Phase III clinical trial for patients with axillary hyperhidrosis. It is also developing therapeutics for cutaneous T-cell lymphoma, psoriasis, and other dermatological conditions. The company was founded in 2009 and is based in Boulder, Colorado. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.851 - 0.855 |
0.855 - 0.858 |
|
Low:
|
0.82 - 0.825 |
0.825 - 0.829 |
|
Close:
|
0.833 - 0.84 |
0.84 - 0.847 |
|
Technical analysis |
as of: 2020-08-14 4:27:40 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 1.04 One year: 1.17 |
| Support: |
Support1: 0.71 Support2: 0.59 |
| Resistance: |
Resistance1: 0.89 Resistance2:  |
| Pivot: |
0.91  |
| Moving Average: |
MA(5): 0.87 MA(20): 0.91
MA(100): 1.10 MA(250): 2.06 |
| MACD: |
MACD(12,26): -0.04 Signal(9): -0.04 |
| Stochastic oscillator: |
%K(14,3): 17.57 %D(3): 21.91 |
| RSI: |
RSI(14): 37.11 |
| 52-week: |
High: 6.51 Low: 0.71 Change(%): -85.9 |
| Average Vol(K): |
3-Month: 188060 10-Days: 51339 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.BBI has closed above bottom band by 0.3%. Bollinger Bands are 67.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to BBI's normal range. The bands have been in this narrow range for 27 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Thu, 13 Aug 2020
The Daily Biotech Pulse: Mesoblast Awaits Adcom Test, BioCryst Rallies On Insider Buying, Sorrento Hits Back At Short Seller - Benzinga
Wed, 12 Aug 2020
Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q2 2020 Results - Earnings Call Transcript - Seeking Alpha
Mon, 03 Aug 2020
Brickell Biotech to Report Second Quarter 2020 Financial Results and Provide a Corporate Update on August 12, 2020 - Yahoo Finance
Fri, 31 Jul 2020
Brickell Biotech, Inc. (NASDAQ:BBI) down -6% over the past 30 days: Any Troubles Ahead? - Marketing Sentinel
Fri, 31 Jul 2020
Boiling and ready to burst as Brickell Biotech Inc. (BBI) last month performance was -6.00% - The InvestChronicle
Tue, 28 Jul 2020
Will current price volatility hamper Brickell Biotech, Inc. (BBI) future potential? - Marketing Sentinel
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NasdaqCM |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
24 |
| Shares Float (M) |
9 |
|
% Held by Insiders
|
14.31 |
|
% Held by Institutions
|
31.99 |
|
Shares Short (K)
|
134 |
|
Shares Short P. Month (K)
|
63 |
Stock Financials |
|
EPS
|
-3.167 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
2.330 |
|
Profit Margin
|
|
|
Operating Margin
|
-428.06 |
|
Return on Assets (ttm)
|
-170.8 |
|
Return on Equity (ttm)
|
|
|
Qtrly Rev. Growth
|
-70.0 |
|
Gross Profit (p.s.)
|
-0.503 |
|
Sales Per Share
|
0.224 |
|
EBITDA (p.s.)
|
-0.957 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-37 |
|
Levered Free Cash Flow (M)
|
-26 |
Stock Valuations |
|
PE Ratio
|
-0.26 |
|
PEG Ratio
|
|
|
Price to Book value
|
0.36 |
|
Price to Sales
|
3.74 |
|
Price to Cash Flow
|
-0.55 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
